Jump to content

DHAP (chemotherapy)

From Wikipedia, the free encyclopedia
(Redirected from R-DHAP)
DHAP
Specialtyoncology

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

[R]-DHAP regimen consists of:

  1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
  2. (D)examethasone, a glucocorticoid hormone
  3. (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
  4. (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.

Dosing regimen

[edit]
Drug Dose Mode Days
Rituximab 375 mg/m2 IV infusion Day 0
Dexamethasone 40 mg PO qd Days 1-4
High-dose Ara-C - cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 2, every 12 hours
Platinol (cisplatin) 100 mg/m2 IV infusion over 24 hrs Day 1

References

[edit]
  1. ^ Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
Retrieved from "https://en.wikipedia.org/w/index.php?title=DHAP_(chemotherapy)&oldid=1236566510"